15-Apr-2015 - L.B. Bohle Maschinen und Verfahren GmbH

With the Technology Center, L. B. Bohle merges all steps of continuous production for the first time

For many years now,continuous processes in pharmaceutical production have been the focus of the special machine builders of L.B. Bohle Maschinen + Verfahren GmbH. With the inauguration of the Technology Center, the engineers, scientists, pharmacists and IT developers for the first time closed the loop control circuit of a modular system along the entireprocess including production, sensor technology and controlling.

"Series production is set to start as soon as we have received FDA clearance. There is no need to develop, install and validate a new production line", explained Dr. Hubertus Rehbaum, Manager Scientific Operation at Bohle.

Two basic ideas are at the core of the successful development project: first of all, the best machines for the individual process steps must be optimally linked to each other, both physically and technically in terms of data. "We have leveraged our acknowledged premium quality in the areas of granulation and coating and, with the companies of Gericke and Korsch, have taken on board another two technology leaders for continuous blending/dosing and tablet press technology," said the initiator Lorenz Bohle.

Secondly, the machines had to be equipped with state-of-the-art sensor and measurement technology and all data had to be integrated on a common platform via standardized interfaces. The software integration, in turn, forms the basis of permanent monitoring, controlling and documentation of the continuous production process. Advanced spectroscopy technologies, such as NIR and Raman, enable precise measurement and analysis during the individual production steps," explained the Manager Scientific Operation, Dr. Rehbaum. Consequently, the leading companies in this area, Kaiser Optical Systems, Sentronic and Kraemer Elektronik, have been involved in the project. Nevertheless, a major challenge arose from directly processing this generated data and making it available for use. Together with the IT partners and university scientists, models had to be developed for simulating various processes as well as for defining and automatically initiating corresponding measures and interventions. "Together, we have developed the intelligence of the system, so to speak," said Dr. Rehbaum. This “evolution process” will continue in the future.

Highly flexible plant

At the Technology Center at the Bohle headquarters in Ennigerloh, customers from the pharmaceutical industry can now experience the benefits of continuous production first hand. "The unique feature of this plant is that the tablet production can be implemented either without granulation or with dry or wet granulation, in one system“, explained Lorenz Bohle. The modular concept of continuous production offers substantial time savings since it does not require any time-consuming analyses of the product samples between the process steps. Moreover, producers benefit from greater flexibility because the plant can be quickly converted to different products.

Investments of more than two million euros

EUR 2 million has been invested in the glass-fronted building alone. "In the coming years, we will make available several million euros for the cooperation in order to push the issue of continuous production further ahead," announced the owner. The permanent measuring, monitoring and controlling of the production throughout the entire process is decisive for the customers. The investor, L. B. Bohle Maschinen + Verfahren GmbH will also manage the Technology Center. "We encourage experts to come to Ennigerloh," commented Lorenz Bohle on the breakthrough of continuous production technologies in the pharmaceutical industry.

Holistic approach as an advantage

This opportunity was also identified by the partner from the University of Düsseldorf, Prof. Peter Kleinebudde: "Given our long-standing and trustful cooperation, it was only natural to join the project as a scientific partner for developing the continuous production line". The "holistic approach" of this new form of production is especially interesting. "The objective is to link the individual process steps and to ensure consistency with constant parameters. To this day, this could not be guaranteed by science", said Prof. Peter Kleinebudde.

Facts, background information, dossiers
  • Bohle
More about Bohle
  • News

    L.B. Bohle receives ATEX-certification

    The European Union published the ATEX-guideline in 1994 first and in 2014 an amended version was implemented. The guideline 2014/34/EU covers equipment and safety systems that are used in hazardous areas. Among others, the sieving machines BTS 100 and BTS 200 built by L.B. Bohle belong to t ... more

    L.B. Bohle rejuvenates management team

    L.B. Bohle Maschinen + Verfahren GmbH has taken advantage of the 2014 business year to prepare itself for the future with investments of several millions. The newly built Technology Center at the Ennigerloh headquarters was inaugurated in March 2015. "Together with customers, partners and s ... more

    Investing in the future: Bohle Technology Center to be opened in March 2015

    Despite a reserved investment climate in the pharmaceutical industry, L.B. Bohle Maschinen + Verfahren GmbH has used the 2014 financial year to prepare itself for the future – with a multi-million euro investment. The new Technology Center at its headquarters in Ennigerloh will open in Marc ... more

  • Videos

    Corporate Video L.B. Bohle Maschinen + Verfahren GmbH


  • Companies

    L.B. Bohle Maschinen und Verfahren GmbH

    L.B. Bohle, with headquarters in Germany, is one of the largest system suppliers for the pharmaceutical industry and related sectors. Operating internationally, the focus is on machines and lines as well as process technology and components. In addition, L.B. Bohle offers efficient and sust ... more